WAVEMAN · COMPANY

ADAG · Adagene Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

ADAG

Name: Adagene Inc. (ADAG) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Adagene Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001818838

C-SUITE BUYING · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

$92.3K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+7332.8%

XBRL, annual

NET MARGIN

-229.6%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$92.3K over 180 days

+$92.3K over 90 days

more than 76% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

27 funds added or opened last quarter

below 65% of Pharma & Biotech

REVENUE

+7332.8% year over year

more than 99% of Pharma & Biotech

MARGIN

-229.6% net margin

below 73% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

3.9% of shares outstanding short · 11.4 days to cover · settled 2026-07-31

below 52% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

27 funds added or opened positions in the latest 13F quarter, of 36 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +68.9%

+68.9%12M

INSIDER BUYFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $92.3K bought by insiders over 180 days, 27 funds added last quarter, $158.0K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Adagene Inc. insiders bought a net $92.3K of stock across 3 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

DO CUONG V

Director

BUY

2026-08-14

2,000.0

$7.5K

Luo Peter

Chief Executive Officer

BUY

2026-08-05

279.0

$1.0K

Luo Peter

Chief Executive Officer

BUY

2026-08-04

22,966.0

$83.7K

3 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Jupiter Topco LLC

6,666,666.0 sh

$28.1M

DEERFIELD MANAGEMENT COMPANY, L.P.

2,666,666.0 sh

$11.2M

Siren, L.L.C.

2,666,666.0 sh

$11.2M

AMERIPRISE FINANCIAL INC

1,716,711.0 sh

$7.2M

HSG Holding Ltd

1,343,364.0 sh

$5.6M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

GU CHUNFANG

FILED 2026-08-19

$158.0K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco Golden Dragon China ETF

$173.4K POSITION · AS OF 2026-04-30

0.2%

Fidelity Nasdaq Composite Index Fund

$30.5K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 5 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

1 ACTIVE

Multi-phase

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$7.7M	$103.2K	$18.1M	$9.3M
OPERATING INCOME	$-21.4M	$-36.0M	$-23.7M	$-83.9M
NET INCOME	$-17.6M	$-33.4M	$-18.9M	$-80.0M
EPS (DILUTED)	-0.30	-0.59	-0.35	-0.31
OPERATING CASH FLOW	$-15.7M	$-29.7M	$-28.5M	$-48.6M
CASH	$74.5M	$85.2M	$109.9M	$143.8M
LONG-TERM DEBT	$1.1M	$417.3K	$13.5M	$14.1M
BUYBACKS	—	—	—	$4.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE